GSC
EW icon

G&S Capital’s Edwards Lifesciences EW Stock Holding History

G&S Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,204
Closed -$249K – 202
2019
Q4 		$249K Buy
3,204
+735
+30% +$57.4K 0.14% 85
2019
Q3 		$181K Buy
+2,469
New +$173K 0.11% 75

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

G&S Capital's EW Position: Q1 2020 in Review

G&S Capital sold out of Edwards Lifesciences (EW) in Q1 2020, closing a stake of 3,204 shares — an estimated $249K sold.

G&S Capital first reported a position in EW in Q3 2019 and held it in 2 quarters. The position peaked at $249K in Q4 2019. 1,019 funds tracked by Wall St. Rank hold EW as of Q1 2020.

  • G&S Capital reported no remaining Edwards Lifesciences position as of Q1 2020 after selling out during the quarter.
  • G&S Capital sold 3,204 Edwards Lifesciences shares in Q1 2020, an estimated $249K.
  • G&S Capital first reported a position in Edwards Lifesciences in Q3 2019 and held it in 2 quarters.
  • G&S Capital's Edwards Lifesciences position peaked at $249K in Q4 2019.
  • 1,019 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2020.

Based on G&S Capital's 13F filing for Q1 2020, filed 23 Apr 2020.